FIP1L1-PDGFRA in eosinophilic disorders

Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature

Animesh D Pardanani, R. P. Ketterling, C. Y. Li, Mrinal M Patnaik, A. P. Wolanskyj, M. A. Elliott, John K Camoriano, J. H. Butterfield, G. W. Dewald, Ayalew Tefferi

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

We previously studied clinico-pathologic features of 89 consecutive adult patients with moderate-to-severe eosinophilia, and reported a FIP1L1-PDGFRA prevalence of 12%. In that series, all 11 FIP1L1-PDGFRA+ patients receiving imatinib achieved a complete response. We now extend our observations through a study of 741 unselected patients with eosinophilia for FIP1L1-PDGFRA, and present longer term follow up data for the imatinib-treated cohort. We also include data for three previously unreported FIP1L1-PDGFRA+ patients. Among the 741 requests, only 21 (3%) were found to carry the FIP1L1-PDGFRA mutation. While all 14 FIP1L1-PDGFRA+ patients receiving imatinib achieved a complete response, the 4 patients who attempted to discontinue imatinib all relapsed. We also find that it is possible to maintain patients in clinical remission with an empirically derived schedule of low-dose (50-100 mg), intermittent (once daily to once weekly) imatinib. Lastly, we present a comprehensive review of the literature pertaining to FIP1L1-PDGFRA in order to address several key aspects of this mutation from a clinical standpoint.

Original languageEnglish (US)
Pages (from-to)965-970
Number of pages6
JournalLeukemia Research
Volume30
Issue number8
DOIs
StatePublished - Aug 2006

Fingerprint

Eosinophilia
Therapeutics
Mutation
Imatinib Mesylate
Appointments and Schedules

Keywords

  • Eosinophilia
  • FIP1L1-PDGFRA
  • Imatinib
  • Mutation
  • Prevalence

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

FIP1L1-PDGFRA in eosinophilic disorders : Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. / Pardanani, Animesh D; Ketterling, R. P.; Li, C. Y.; Patnaik, Mrinal M; Wolanskyj, A. P.; Elliott, M. A.; Camoriano, John K; Butterfield, J. H.; Dewald, G. W.; Tefferi, Ayalew.

In: Leukemia Research, Vol. 30, No. 8, 08.2006, p. 965-970.

Research output: Contribution to journalArticle

@article{476a36dc56314cefabaa75c67c0fd20d,
title = "FIP1L1-PDGFRA in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature",
abstract = "We previously studied clinico-pathologic features of 89 consecutive adult patients with moderate-to-severe eosinophilia, and reported a FIP1L1-PDGFRA prevalence of 12{\%}. In that series, all 11 FIP1L1-PDGFRA+ patients receiving imatinib achieved a complete response. We now extend our observations through a study of 741 unselected patients with eosinophilia for FIP1L1-PDGFRA, and present longer term follow up data for the imatinib-treated cohort. We also include data for three previously unreported FIP1L1-PDGFRA+ patients. Among the 741 requests, only 21 (3{\%}) were found to carry the FIP1L1-PDGFRA mutation. While all 14 FIP1L1-PDGFRA+ patients receiving imatinib achieved a complete response, the 4 patients who attempted to discontinue imatinib all relapsed. We also find that it is possible to maintain patients in clinical remission with an empirically derived schedule of low-dose (50-100 mg), intermittent (once daily to once weekly) imatinib. Lastly, we present a comprehensive review of the literature pertaining to FIP1L1-PDGFRA in order to address several key aspects of this mutation from a clinical standpoint.",
keywords = "Eosinophilia, FIP1L1-PDGFRA, Imatinib, Mutation, Prevalence",
author = "Pardanani, {Animesh D} and Ketterling, {R. P.} and Li, {C. Y.} and Patnaik, {Mrinal M} and Wolanskyj, {A. P.} and Elliott, {M. A.} and Camoriano, {John K} and Butterfield, {J. H.} and Dewald, {G. W.} and Ayalew Tefferi",
year = "2006",
month = "8",
doi = "10.1016/j.leukres.2005.11.011",
language = "English (US)",
volume = "30",
pages = "965--970",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - FIP1L1-PDGFRA in eosinophilic disorders

T2 - Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature

AU - Pardanani, Animesh D

AU - Ketterling, R. P.

AU - Li, C. Y.

AU - Patnaik, Mrinal M

AU - Wolanskyj, A. P.

AU - Elliott, M. A.

AU - Camoriano, John K

AU - Butterfield, J. H.

AU - Dewald, G. W.

AU - Tefferi, Ayalew

PY - 2006/8

Y1 - 2006/8

N2 - We previously studied clinico-pathologic features of 89 consecutive adult patients with moderate-to-severe eosinophilia, and reported a FIP1L1-PDGFRA prevalence of 12%. In that series, all 11 FIP1L1-PDGFRA+ patients receiving imatinib achieved a complete response. We now extend our observations through a study of 741 unselected patients with eosinophilia for FIP1L1-PDGFRA, and present longer term follow up data for the imatinib-treated cohort. We also include data for three previously unreported FIP1L1-PDGFRA+ patients. Among the 741 requests, only 21 (3%) were found to carry the FIP1L1-PDGFRA mutation. While all 14 FIP1L1-PDGFRA+ patients receiving imatinib achieved a complete response, the 4 patients who attempted to discontinue imatinib all relapsed. We also find that it is possible to maintain patients in clinical remission with an empirically derived schedule of low-dose (50-100 mg), intermittent (once daily to once weekly) imatinib. Lastly, we present a comprehensive review of the literature pertaining to FIP1L1-PDGFRA in order to address several key aspects of this mutation from a clinical standpoint.

AB - We previously studied clinico-pathologic features of 89 consecutive adult patients with moderate-to-severe eosinophilia, and reported a FIP1L1-PDGFRA prevalence of 12%. In that series, all 11 FIP1L1-PDGFRA+ patients receiving imatinib achieved a complete response. We now extend our observations through a study of 741 unselected patients with eosinophilia for FIP1L1-PDGFRA, and present longer term follow up data for the imatinib-treated cohort. We also include data for three previously unreported FIP1L1-PDGFRA+ patients. Among the 741 requests, only 21 (3%) were found to carry the FIP1L1-PDGFRA mutation. While all 14 FIP1L1-PDGFRA+ patients receiving imatinib achieved a complete response, the 4 patients who attempted to discontinue imatinib all relapsed. We also find that it is possible to maintain patients in clinical remission with an empirically derived schedule of low-dose (50-100 mg), intermittent (once daily to once weekly) imatinib. Lastly, we present a comprehensive review of the literature pertaining to FIP1L1-PDGFRA in order to address several key aspects of this mutation from a clinical standpoint.

KW - Eosinophilia

KW - FIP1L1-PDGFRA

KW - Imatinib

KW - Mutation

KW - Prevalence

UR - http://www.scopus.com/inward/record.url?scp=33646532818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646532818&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2005.11.011

DO - 10.1016/j.leukres.2005.11.011

M3 - Article

VL - 30

SP - 965

EP - 970

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -